Celldex reports Q1 net loss $32.8M; cash $823.8M; Phase 3 CSU studies planned summer 2024

Celldex Therapeutics, Inc.

2024-Q1 EPS reported -$0.56 revenue$156,000

Net loss of $32.8M ($0.56 per share) vs $29.4M ($0.62) in Q1 2023; revenue $0.2M.
Cash, cash equivalents and marketable securities $823.8M, up from $423.6M due to $432.3M net public offering.
Phase 3 CSU studies to initiate summer 2024; 52-week Phase 2 CSU data expected H2 2024.
Phase 2 CIndU enrollment completed (196 patients); 12-week data due H2 2024.
Atopic dermatitis selected as fifth indication; Phase 2 study to start by year-end 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Celldex Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 6, 2024, Celldex Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the first quarter of 2024.

View on SEC.gov

710 earnings releases filed in the last 30 days. Browse all earnings releases →

Celldex Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-24-002570

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.